Targeting Tumor-Intrinsic Pathways to Enhance Immunotherapy

Throughout history, various approaches including surgery, radiation therapy, chemotherapy, and targeted therapy have been employed in the fight against cancer. In the 2010s, the emergence of immunotherapy marked a significant turning point in cancer treatment, leveraging our own immune system to combat cancer. Despite its breakthroughs, immunotherapy faces challenges such as resistance, both initially and over time. Our focus is on enhancing immunotherapy by targeting intrinsic pathways within cancer cells. Specifically, we examine two types of cancer cells: regular (differentiated) cancer cells and cancer stem cells (tumor-initiating cells). Join us as we delve into these research directions, illuminating our efforts to advance cancer treatment through innovative approaches.

Learning Objectives: 

1. Review targeting FBXO44/SUV39H1 pathway in cancer cells to enhance anti-PD1 immunotherapy. 

2. Summarize targeting novel regulators in glioblastoma stem cells for NK cell-based immunotherapy.

3. Explain viral mimicry strategy in cancer immunotherapy.